Lee, Andrew
February 2003
Engineer (00137758);2/7/2003, Vol. 291 Issue 7620, p23
Reports on developments regarding engineering as of February 7, 2003. Osmetech's deal with Roche; Plan of BAE Systems to exit the space industry; Major licensing deal of Imagination Technologies with Sharp; Phoenix Inspection Systems' goal of developing new ways for critical safety checks of nuclear reactors.


Related Articles

  • Matthias Waehren. TRANSFORMING FINANCE AT ROCHE-NUTLEY PHARMACEUTICALS. Williams, Kathy; Hart, James // Strategic Finance;Sep2000, Vol. 82 Issue 3, p46 

    The article presents information about the transformation of the financial processes in Roche Group's United States pharmaceuticals business. The role of Matthias Waehren, vice president of finance and information technology, is examined. A discussion is presented about the administration of the...

  • Roche's Rush. Kingsbury, Kathleen // Time International (South Pacific Edition); 

    The article offers information about the U.S. pharmaceutical company Roche. In spite of sale profits reaching $30 billion for 2007, the company is receiving pressure to achieve quicker and more reliable research and development results. Improvement strategies include finding inspiration in...

  • SNDA FILED FOR XENICAL AS TYPE 2 DIABETES TREATMENT OPTION.  // Worldwide Biotech;May2001, Vol. 13 Issue 5, p3 

    Reports that Roche has announced that a supplemental New Drug Application has been submitted to the United States Food and Drug Administration for Xenical.

  • Roche moves OTC work in central Europe to Saatchi.  // Advertising Age's Euromarketing;8/6/96, Vol. 9 Issue 47, p1 

    Reports that Roche Consumer Health of eastern Europe has awarded Saatchi & Saatchi the advertising accounts for its Supradyn, Rennie, Aspro and Bepanthene brands. Value of the account.

  • Roche invests in proteomics programme.  // Life Science Today;Dec2000, Vol. 1 Issue 6, p7 

    Focuses on the total amount of money allotted by Roche to link proteomics research in the pharmaceuticals and diagnostics division of the company in Switzerland. Description of proteomics; Accounts on the gene function in the post-genomic era; Identification of the protein used as potential...

  • Roche. Valdmanis, Thor // Financial World;5/20/96, Vol. 165 Issue 8, p24 

    Features Swiss drugmaker Roche. Merger of Roche's rivals Sandoz and Ciba-Geigy; Displacement of Roche as a Switzerland's top pharmaceutical concern; Growing trend towards large pharmaceutical companies worldwide.

  • No sale.  // WWD: Women's Wear Daily;2/7/1997, Vol. 173 Issue 26, p10 

    Reports on the impact of Roche Holdings Ltd.'s announcement to acquire a United States-based flavors business on speculations about the sale of Givaudan-Roure, its fragrance flavors division.

  • Roche rush.  // njbiz;7/2/2012, Vol. 25 Issue 27, p11 

    The article contends that to say that the decision of pharmaceutical company Roche to close its Nutley, New Jersey, operation came as a shock would be an understatement.

  • Lean growth. Gopal, Kevin // Pharmaceutical Executive;Dec97, Vol. 17 Issue 12, p34 

    Reports on the plan of Roche to streamline the number of its employees following the integration of Boehringer Mannheim and DePuy units. Plans to minimize compulsory redundancies and implement reductions in socially responsible manner; Offering of positions at other sites to staff.


Other Topics